Cell line · CVCL_A8EZ
Papers40
1 to 20 of 40
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Oral proton-reprogrammed nanomedicine to break the inflammatory bowel disease-Clostridium difficile infection vicious cycle. | Imeta | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Selenium Nanoparticles Selectively Target KRAS G13D to Inhibit Colorectal Cancer. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dihydroartemisinin inhibits mutant KRAS to potentiate regorafenib plus anti-PD-1 in KRAS-mutant colorectal cancer liver metastases. | Cell Death Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FUT2-Mediated Fucosylation of OLFM4 Promotes Colon Cancer Cell Differentiation. | Can J Gastroenterol Hepatol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PI3K and MAPK Signaling Nodes Serve as Divergent Drivers of Phenotypic Plasticity in Cancer-Associated Fibroblasts in Colorectal Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| METTL3 Methylation Induces Decay of Endogenous Retroelement Transcripts to Promote Tumor Immune Evasion. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Orosomucoid 2 promotes colorectal cancer liver metastasis by suppressing natural killer cell-mediated antitumor immunity by remodeling the serine and one-carbon metabolism pathway. | Mol Cancer | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer. | Cell Rep Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FASN Inhibition Enhances the Efficacy of Chemotherapy in Colorectal Cancer by Inhibiting the DNA Damage Response. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| MYLK4 promotes colorectal cancer progression by regulating lipid metabolism reprogramming via targeting ferroptosis. | Neoplasia | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The subtype identification of colorectal cancer and construction of the risk model based on cholesterol synthesis-related genes to predict prognosis and guide immunotherapy. | Int J Colorectal Dis | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Lipid Droplet-Localized Spindle Apparatus Coiled-Coil Protein 1 Regulates Lipid Droplet Distribution. | Adv Sci (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The Recycling Collagen Receptor uPARAP Is a Unique Mediator of Stromal Drug Delivery to Carcinoma Cells. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| KDM3B promotes neural invasion in colorectal cancer through TrkA upregulation by inhibiting H3K9 dimethylation. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| New drug targets for acute myeloid leukemia identified through a comprehensive analysis of the plasma protein. | BMC Cancer | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting CAD with a tumor microenvironment-responsive nano-heterojunction for synergistic induction of cuproptosis and inhibition of colorectal cancer progression. | J Nanobiotechnology | 2025 | Its Methods give the RRID and name the line | PubMed | |
| circ-EGFR is a predictor of response to Cetuximab and a potential target in colorectal cancer. | EMBO Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| The Role of NOL3 in Colon Adenocarcinoma Metastasis and Its Association With DNA Methylation. | Hum Mutat | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Pathway metabolite ratios reveal distinctive glutamine metabolism in a subset of proliferating cells. | Mol Syst Biol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Functional characterization of the ATOH1 molecular subtype indicates a pro-metastatic role in small cell lung cancer. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_A8EZ/papers